Cleveland BioLabs, Inc. (NASDAQ:CBLI) notched a 9.72% intraday gain moving at $1.58. When the opening bell rang, the price was $1.43. The number of shares that were traded during the day was 775034, which corresponds to its 1-week volume average of 161100 shares a day.

Cleveland BioLabs, Inc. Earnings Surprise

Revenue had a distance of -26.1% from the previous quarter, with the company recording $2.86 million in revenue.

Cleveland BioLabs, Inc. (NASDAQ:CBLI) Intraday View

The shares of Cleveland BioLabs, Inc. (NASDAQ:CBLI) have struggled and recovered 58% ever since it recorded its 52 week low. During the course of 5 days, the stock price volatility has remained at 9.02%, increasing the time frame to a month, the volatility recorded was 6.08%. The price of their shares still hasn’t been successful in staying above its 20 day-moving average, staying at a distance of -2.16% and while its 50-day moving average is around 1.98%. In a look at the previous five trading session CBLI stock has returned -1.25% and sank -10.42% when compared to its 200-day moving average that is $1.5883. Cleveland BioLabs, Inc. (CBLI) will look to overcome its -44.37% fall that it witnessed in the past year.

As the normal trading session ended, the stock of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), fetched in a $0.06 spike to $1.13. The session began with the stock price at $1.07, hitting a high of $1.14 before down again. For the week, analysts seem to be okay with their neutral with the consensus call staying at 2.2. Tetraphase Pharmaceuticals, Inc. gets 1 buy analyst recommendations while 2 recommend a hold and 0 rated it as a sell. The shares of the company tumbled -74.83% from its high $4.49, with their overall market value now roughly $62.47 million.

Tetraphase Pharmaceuticals, Inc. (TTPH) Consensus Price Target

The mean recommendation of TTPH on Reuter’s scale upped from 2.14 to 2.17 within 30 days. This figure implies that the majority of analysts rate it as a hold. The price target for Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) is now around $6.75 a share, implying the stock has what it takes to grow by 497.35%. The recent trading session also indicated the stock needs to add 784.96% more meet analysts’ high consensus price target.

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Intraday Trading

The current trading volume of the company was 566149 shares during the last session. That compares with the recent average volume of 607560 shares. By the end of the regular trading session, the price volatility over a 1-week span was 7.07 % while over a month it stood at 6.32%. The stock price of TTPH dropped to $1.05 during the day and at a certain time in 12 months it traded as low as $1.01. It has made a 11.88% recovery since its 52-week low point and has returned 0% year-to-date. [T3]